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Abstract 
We have profiled, for the first time, an evolving human metastatic microenvironment, 
measuring gene expression, matrisome proteomics, cytokine and chemokine levels, 
cellularity, ECM organization and biomechanical properties, all on the same sample. Using 
biopsies of high-grade serous ovarian cancer (HGSOC) metastases that ranged from minimal 
to extensive disease, we show how non-malignant cell densities and cytokine networks 
evolve with disease progression. Multivariate integration of the different components allowed 
us to define for the first time, gene and protein profiles that predict extent of disease and 
tissue stiffness, whilst also revealing the complexity and dynamic nature of matrisome 
remodeling during development of metastases. Although we studied a single metastatic site 
from one human malignancy, a pattern of expression of 22 matrisome genes distinguished 
patients with a shorter overall survival in ovarian and twelve other primary solid cancers, 
suggesting that there may be a common matrix response to human cancer. 
 
Keywords 
Tumor microenvironment, extracellular matrix, biomechanics, cytokines, tumor-infiltrating 
leukocytes, ovarian cancer, cancer-associated fibroblasts, data integration  
Significance 
Conducting multi-level analysis with data integration on biopsies with a range of disease 
involvement identifies important features of the evolving TME. The data suggest that despite 
the large spectrum of genomic alterations, some human malignancies may have a common 
and potentially targetable matrix response which influences the course of disease. (50 words)  
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Introduction 
Solid tumors consist of malignant cells surrounded and infiltrated by a variety of host cells 
that are recruited and ‘corrupted’ by the cancer, aiding its growth and spread (1,2). A 
dynamic network of soluble factors, cytokines, chemokines, growth factors and adhesion 
molecules drive the interactions between malignant and non-malignant cells to create this 
tumor microenvironment (TME) (3,4). The TME network stimulates extracellular matrix 
(ECM) remodeling, expansion of abnormal vascular and lymphatic networks and migration 
of cells into and out of the tumor mass (5,6). Solid tumors are also typically stiffer than the 
surrounding tissue due to aberrant ECM deposition and organization that has a major 
influence on cell and tissue mechanics (7,8). 
While the TME is of critical importance during initiation and spread of cancer, relatively 
little is known about its evolution or the relationship between the molecular mechanisms of 
disease progression and higher-order features such as the extent of disease, non-malignant 
cell density and tissue stiffness. Studies on molecular mechanisms of human cancer have 
mainly focused on large-scale genomic and transcriptomic analysis of primary tumors (9) and 
the immune cell landscape (1). Human cancer evolution is also now being studied in multiple 
metastatic sites e.g.(10,11) but mainly in terms of the genomics of the malignant cells. Also, 
most of these analyses focus on one stage of a cancer. 
Here, for the first time, we have used multi-layered TME profiling of a metastatic site, 
omental metastases of high-grade serous ovarian cancer (HGSOC), to identify molecular 
changes that predict the higher-order TME features. Our study differs from other genomic 
and transcriptomic studies in two important ways: first, we have integrated data from six 
different TME parameters from each metastatic sample studied and second, we have studied 
the evolution of metastases by including samples that vary in the extent of disease.  
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HGSOC is one of the most lethal of the peritoneal cancers: less than 30% of patients 
currently survive more than five years after diagnosis with little improvement in overall 
survival in the past 40 years (12). As poor prognosis is mainly due to early dissemination into 
the peritoneal cavity (12,13) and HGSOC metastases have a complex TME (14), there is a 
need for an integrated understanding of its different components (12). We chose to study the 
omental TME because it is the most frequent site for HGSOC metastases and is routinely 
resected during debulking surgery.  
Using samples ranging from minimal to extensive disease we conducted cellular, 
biomechanical and molecular analyses on each biopsy. Integration of the different 
components using multivariate analyses allowed us to define for the first time, gene and 
protein profiles that predicted extent of disease and tissue stiffness whilst also revealing how 
the ECM is remodeled during metastases development. Of particular interest was an ECM-
associated molecular signature, that we termed the matrix index, that predicted both extent of 
disease and tissue stiffness in our sample set. This novel signature distinguished patients with 
shorter overall survival not only in ovarian cancer, but also in twelve other cancer types 
irrespective of patient age, stage or response to primary treatment, suggesting a common 
matrix response to human primary and metastatic cancers. 
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Results 
Study Design 
We analysed six different parameters of omental biopsies from 36 HGSOC patients: the 
extent of disease, densities of non-malignant cells, tissue mechanics, cytokines, matrisome 
protein and RNA profiles (Figure 1A). The samples ranged from uninvolved or minimally-
diseased omentum to biopsies with extensive disease (Table S1, Figure 1B and Figure S1A).  
The extent of disease in each biopsy was measured by digital histopathology on haematoxylin 
and eosin (H&E) stained sections and was calculated as the percentage of tissue area 
occupied by malignant cells and stroma. We termed this the ‘disease score’. Remodeling of 
the omentum was extensive when malignant cells were present and the malignant cells 
comprised a minor proportion of the tissue (Figure 1B). In order to monitor for any 
significant changes in sample architecture during tissue processing for the different analyses 
we took serial sections for H&E staining. We did not observe any major changes in disease 
score between the different areas analyzed.  
The density of the major non-malignant cell populations was measured by 
immunohistochemistry (IHC) and digital histopathology in the same specimens. The 
biomechanical properties of the tissues were measured using a mechanical indentation 
methodology (15) that gave us the tissue modulus of each sample. 
Twenty-nine cytokine and chemokines were measured in protein lysates using an electro-
chemiluminescence assay (Table S2). For proteomic analysis of the same biopsies we 
focused on the ECM and associated molecules using a method that enriches whole tissue 
lysates for the matrisome protein compartment (16). Using this technique we detected 145 
proteins (Table S3). The term ‘matrisome’ is defined as the ensemble of all core ECM 
proteins (collagens, proteoglycans, glycoproteins) and associated molecules (the secretome, 
ECM-regulators and ECM-affiliated molecules) of tissue extracellular matrices (17). After 
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alignment and filtering, RNA sequencing identified 15,441 protein-coding genes (Table S4). 
We then used univariate analyses and a multivariate regression method – partial least squares 
(PLS) (18) – to model the relationships between these different components of the metastases 
(Figure 1C).  
 
The relationship between cell density and disease score  
Using a tissue microarray constructed from the biopsies we quantified the adipocytes, 
fibroblasts and leukocytes which were the major non-malignant components in the specimens 
and related this to disease score. The area occupied by adipocytes, the major cell type of the 
normal omentum, decreased with disease score (Figure 1B) and this was in part due to a 
reduction in the diameter of the adipocytes (Figure 2A) which may reflect research showing 
that adipocytes can provide energy for ovarian cancer cell growth (13). Using α-smooth 
muscle actin (-SMA) and α-fibroblast activation protein (α-FAP) as markers of cancer-
associated fibroblasts (CAFs) (19), we assessed the area of the tissue occupied by -SMA+ 
and α-FAP+ cells and found a strong positive correlation with disease score for both markers 
(Figure 2B, C).  
We then stained and counted six major leukocyte subtypes and plotted cell density against 
disease score. In all cases there was a significant positive correlation between leukocyte 
density and disease score (p<0.001) (Figure 2D, Figure S1B). Densities of T cells with the 
surface markers CD3, CD4, CD8 and CD45RO strongly correlated with each other (p<0.001, 
r>0.6) but CD68+ macrophage density only weakly correlated with the other leukocytes 
(p<0.05, r<0.5) (Figure 2E, Table S5).  
Therefore, as metastases developed in the omentum, the fatty tissue was replaced by a 
combination of fibroblasts, lymphocytes and macrophages. The cellular composition that we 
observed illustrates the changes from a normal omental tissue, primarily composed of 
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adipocytes with minimal immune cell infiltrate and little fibroblastic reaction, to heavily 
diseased tissues with profound tumor-associated inflammation and a large increase in all 
types of leukocytes and fibroblasts. However, whilst there was a general increase in stromal 
cell density across all of the markers we studied, we observed larger variance with high 
disease score samples for all immune cell counts. This is to be expected as it is already well-
documented that the TME of advanced HGSOC biopsies ranges from sparse to dense 
leukocyte infiltration.  
The immune cell densities significantly correlated with their corresponding immune gene 
expression signatures extracted from the associated RNAseq data for each sample (Table S6) 
and levels of the adipogenic transcription factor PPAR mRNA declined with disease score 
(Figure S1C). Thus, the cell density scores were validated by the gene transcription data. 
 
Leukocyte density and cytokine networks in the TME 
Next, we correlated leukocyte density against levels of 29 different cytokines and 
chemokines in protein lysates of the metastases. There were eight significant correlations 
(Figure 2F, Table S7), the strongest of which was, unexpectedly, an association between 
IL16, a chemoattractant and modulator of T cell function, and the density of CD3, CD45RO 
and CD8 cells. These correlations became stronger with the 10 samples with the highest 
disease score (Figure S1D). IHC revealed IL16 protein in both malignant and stromal areas, 
with a higher density in the former (Figure 2G). There was also a high positive correlation 
between global cell proliferation assessed by Ki67 and LTA, IL17A, IL15, CXCL10 (Figure 
2F).  
 As cytokine networks are major determinants of leukocyte density and phenotype in the 
TME (3,20), we asked if the cytokine proteins and genes we detected in the tissue lysates 
could inform us about the networks that regulate omental metastases. We constructed 
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heatmaps showing pairwise comparisons of cytokine protein and gene transcription levels 
(Figure 2H, Figure S1E, Tables S8 and S9). Overall the protein gene correlation was 30%, in 
line with other studies e.g. (21). The heatmaps show five significant co-expressions at both 
gene and protein level: IL6 with IL1A, IL1B, and IL8, CSF2 with IL8, and CCL4 with 
CCL3.  IL6 was of particular interest as we previously identified this as a major mediator of 
cytokine networks in ovarian cancer (20,22). Finally, we asked if levels of any of the 
cytokines and chemokines associated with disease score. There were weak but significant 
associations with disease score with IL12B, IL13, IL16, VEGF, CCLs 11, 26, and CXCL10.  
 
These results suggest that malignant cell-derived cytokine and chemokine networks in the 
omental metastases regulate leukocyte density and overall proliferative index. Unexpectedly, 
we identified the CD4 ligand IL16 as a potential major mediator of the leukocyte infiltrate. It 
is interesting that increased tissue and serum levels of IL16 have been reported during tumor 
development in laying hen models of ovarian cancer and in ovarian cancer patients (23).  
 
These cytokine and cellularity data confirm and extend previous research on the ovarian 
cancer and other tumor microenvironments and we believe validate our approach. Extensive 
study of another TME component, the matrisome, has recently become possible through 
proteomics methods that focus on these proteins (17). There is currently little information on 
how the matrisome evolves with disease progression. Therefore, our next aim was to study 
the ECM-associated proteins and genes, collectively termed the matrisome, in the same 
biopsies.  
 
How the matrisome changes with disease progression 
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Using our matrisome-focused proteomic technique (16) and the RNAseq data we 
quantitatively assessed matrisome proteins and genes. In terms of relative mass ratios, the 
major matrix proteins in samples with the lowest disease score were collagen 1, 6 and 3, the 
glycoprotein fibrillin, the ECM regulator alpha-2-macroprotein, and the basement membrane 
proteoglycans lumican and heparin sulphate proteoglycan-2. In contrast, biopsies with the 
highest disease score had an expansion of ECM-glycoproteins fibrinogen and fibronectin, as 
well as increases in proteoglycans, secreted factors, and affiliated proteins, (FDR <0.1) 
(Figure 3A).  
Extending the analysis to the entire sample set we found that as disease score increased levels 
of some matrisome proteins decreased and others increased. Comparing the relative mass 
ratio of all matrisome proteins with disease score, we found that 18 proteins decreased and 49 
proteins increased with disease progression (Figure 3B, Table S10).  After these univariate 
analyses, we used the multivariate regression PLS method to rank genes and proteins 
according to their influence on disease score, and a permutation-derived threshold was 
applied to determine those that were most strongly associated with disease score (24,25).  
Of these, 58 proteins ranked top in PLS modeling of disease score (r
2
 = 0.70), defining a 
matrisome protein signature of disease score (Figure 3C, Table S11).  
412 of the 764 matrisome genes detected in our transcriptomics dataset also predicted disease 
score (Table S12). The top 60 genes are shown in Figure 3D with 27 ECM-associated 
molecules predicting disease score at both the gene and protein level (Figure 3E, Figure 
S2A). We used IHC to detect four of these proteins, FN1, COMP, CTSB and COL11A1, in 
HGSOC omentum detecting all four within stromal regions (Figure 3F). As collagen 
organisation strongly influences cell behavior and tissue mechanics (26,27), we utilised two-
photon microscopy to visualise collagen fibres using second harmonic generation (SHG) 
label-free illumination (Figure 3G). In low disease score tissues collagen fibres were thin and 
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arranged mostly around the adipocytes. In high disease score tissues, there were denser arrays 
of long collagen bundles with an apparent micro-scale orientation preference. Collagen 
orientation correlated strongly with disease score (Figure 3G). It should be noted that Figure 
3A shows relative matrisome protein abundance as mass ratios whereas Figure 3G depicts the 
alignment of collagen in the tissues. While the amount of collagen does increase in diseased 
tissue, its relative abundance goes down as other matrisome proteins are induced as the tissue 
becomes more diseased. Representative images for COL1A1 IHC staining are shown in 
Figure S2B. 
 
Other biological processes associated with disease score 
We then analysed the RNAseq data to find other biological processes associated with disease 
score (Table S13). Significantly associated pathways included cell metabolism, adhesion, 
communication as well as ECM organization and immune response pathways (Figure S2C, 
Table S14). 
 
We have described here, for the first time, how the matrisome changes with disease 
progression. As some of the strongest correlations with disease score were found with these 
ECM-associated proteins and genes, and increased tissue stiffness has been linked with tumor 
progression (28,29), we next investigated how the changes in matrisome genes and proteins 
related to the biomechanical properties of the biopsies. 
 
Relationships between tissue modulus (stiffness) and disease score 
We used mechanical indentation (15) to determine tissue modulus (which describes material 
stiffness independent of sample size) and the stress-relaxation behavior of the samples. We 
measured disease score from histological sections of the area of the specimen that was 
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indented (Figure 4A, Figure S3). Biopsies with a high disease score displayed a non-linear 
loading response and greater stress relaxation while there was a relatively linear loading 
response in low disease score tissue (Figure 4B, Figure S3C, Table S15). Tissue modulus 
values in high disease score biopsies were one-two orders of magnitude higher than in low 
disease biopsies. There were significant positive correlations between tissue modulus and 
malignant cell area, the stromal area and disease score of each biopsy (Figure 4C, Figure 
S3D). Thus, there was a significant log relationship between tissue modulus and disease score 
in the evolving TME suggesting a close association of tissue stiffness with disease 
progression. 
 
The matrisome, tissue stiffness and disease score 
Using the PLS method, we identified 64 matrisome proteins, mainly glycoproteins, that 
accurately predicted tissue modulus (r
2
 = 0.69) (Figure 4D, Figure S4A, Table S16). We then 
used 764 matrisome genes detected by RNAseq and identified 405 that predicted tissue 
modulus (Figure 4E, Figure S4B, Table S17) of which 38 also featured as proteins in Figure 
4D. Thus, as with disease score, the tissue modulus could be predicted by a subset of ECM-
associated genes and proteins of the matrisome. 
We also modeled tissue modulus against the entire transcriptome of the metastases (Figure 
S4C, Table S18). Genes associated with cell metabolism, cell communication, wound 
healing, ECM organization, as well as development, correlated with tissue modulus (Figure 
S4D, Table S19). Figure 4F shows the PLS prediction plot and the top 50 genes from this 
signature. As expected there was a strong overlap with disease score-associated genes and 
proteins (74% and 75% respectively) and these were significantly associated with tissue 
modulus (Table S20). 
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Collectively, the experiments described above demonstrated the complexity and dynamic 
nature of matrisome evolution during development of HGSOC metastases and the close 
relationship between tissue stiffness and extent of disease. 
  
A subset of matrisome molecules models both disease score and tissue modulus and has 
prognostic significance in HGSOC 
We next asked how many matrisome genes and proteins significantly defined both disease 
score and tissue modulus in our sample set (Figure 5A, Table S21). Twenty-two molecules 
were highly significant across all of our analyses with a gene:protein concordance of 68% 
(Figure 5A, Figure S5A). Thirteen of the 22 proteins had documented protein:protein 
interactions (Figure 5B). Using the ChEA database (30) we found that the 22 genes shared a 
range of common transcription factors including RUNX2, STAT3, SMAD4, WT1, JUN and 
TP53. These reflect pathways associated with Wnt signalling pathway, inflammation and 
osteogenesis, whilst TP53 is of course the most frequently mutated gene in HGSOC, a major 
genetic driver of the disease (Figure S5B and Table S22). 
Using these 22 most significant molecules, we measured the ratio between the mean 
expression levels of the positively regulated genes and the mean expression levels of the 
negatively regulated genes. We termed this the matrix index because these molecules are all 
components of the matrisome (17). As would be expected, the matrix index of each sample 
significantly correlated with disease score and tissue modulus in our set of samples 
(p<0.0001) as would be expected (Figure 5C). There were also significant positive and 
negative correlations between matrix index and immune cell signatures in the corresponding 
RNAseq data (Figure 5D, Table S23), notably Treg and Th2 cell signatures, cell subtypes 
associated with tumor promotion and immune suppression (31) and a modest statistically 
significant relationship between disease score and entropy as a measure of clonal abundance 
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for T and B cells (Table S23).  These data suggest that matrix index molecules may influence 
expansion of specific infiltrating cell populations. In support of these findings, there were 
significant linear correlations between the matrix index and the data in Figure 2 in terms of 
CD4+ (pearson r=0.523, p=0.001) and FOXP3+(pearson r=0.52, p=0.001) cells but there was 
no correlation between matrix index and CD8+ cells (pearson r=0.29, p=0.094). 
 
Relevance of matrix index to other stages of HGSOC and prognosis  
As the matrix index positively correlated with disease score, tissue modulus and immune-
suppressive signatures in our sample set, we wondered if it would distinguish ovarian cancer 
patients with a poorer prognosis in transcriptomic data from untreated primary tumors. We 
extracted expression values from two publicly available HGSOC gene expression datasets 
and calculated the matrix index for each sample. The high and low matrix index groups were 
determined using a method described previously (32). High matrix index significantly 
correlated with shorter overall HGSOC patient survival in both the ICGC and TCGA gene 
expression datasets, as well as in our original sample set (Figure 5E, Figure S5B-E). To test 
that the clinical outcome association of the matrix index was not a random finding we 
conducted 200,000 simulations and found that the association was significantly above that 
expected from random signatures.  
In order to account for the higher relative abundance of tumor cells compared with stroma 
present in the TCGA ovarian cancer samples compared to our samples, we plotted the 
correlation between matrix index and % tumor cell or % stroma in each TCGA sample. In 
both cases we observed no association with matrix index (Figure S5F). Taken together with 
the immune cell correlations, this further suggests the matrix index is not only a measure of 
the tissue remodeling that accompanies HGSOC, but is also a measure of a matrisome 
composition that better supports tumor progression.  
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Interrogating the TCGA ovarian cancer dataset, we next evaluated the power of the matrix 
index against nine other well-known prognostic gene expression signatures in ovarian and 
other cancers, including signatures for stromal and immune responses (33-41). In terms of 
hazard-ratio scores, matrix index was in the top three after the 26-gene breast cancer stromal 
signature reported by Finak et al (41) and the 193-transcriptional signature from TCGA (9) 
(Figure 5F, left panel). However, using multivariate analysis, matrix index was the single 
significant predictor of ovarian cancer survival independently of age, stage, grade and 
treatment outcome (Figure 5F, right panel and Table S24).  
At the protein level, we used matrix index to examine the recently released TCGA/CPTAC 
ovarian cancer proteomics dataset.  Whilst the study was not focused on detecting ECM 
proteins, which requires matrisome protein enrichment prior to analysis, as described above, 
we found that there were 12 proteins from the matrix index with a significant association with 
survival (10 with p < 0.05 and a further 2 with p < 0.1).  
 
Matrix Index in other human cancers  
ECM remodeling is a common feature of many human cancers and significant desmoplasia 
and ECM deposition is found in other solid tumors. Since we hypothesize that the matrix 
index is a measure of a tumor-promoting matrisome in HGSOC, we wondered if it may also 
be a feature associated with poor outcome in other cancer types. We calculated matrix index 
values in 30 other publicly available gene expression datasets from epithelial, mesenchymal 
and haematologic malignancies analysing data from 9215 human cancer biopsies. High 
matrix index was an indicator of poor prognosis in epithelial and mesenchymal cancers but 
not in haematological cancers, melanoma and glioblastoma (Figure 6A and Figure S6A). 
Using univariate analysis, high matrix index predicted shorter overall patient survival in 15 
datasets representing 13 major cancer types (p < 0.05) (Figure S6B, Table S25). The range of 
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matrix index values across all these cancer databases had a median value close to 1.0 (Figure 
S6C). We believe this provides further evidence that the pattern of ECM-associated gene 
expression determined by the matrix index may be a common feature of human cancers. 
Remarkably, multivariate analysis showed that the prognostic value of the matrix index was 
independent of age, stage, grade and response to primary treatment in 15 of the datasets 
representing 13 major cancer types (p < 0.05) (Figure 6B).  
Using IHC, we confirmed the presence of four of the upregulated matrix index proteins FN1, 
COL11A1, CTSB, and COMP, in three tissue microarrays from triple negative breast cancer 
(TNBC), pancreatic ductal adenocarcinoma (PDAC), and diffuse large B-cell lymphoma 
(DLBCL) (Figure 6C). These cancers reflected the range of hazard ratios for high matrix 
index in Figure 6B. Digital microscopy analysis showed the highest staining level in TNBC 
(Figure 6D), in keeping with the matrix index score for this cancer (Figure S6C). FN1, 
COMP, and CTSB were present in stroma and fibroblastic cells of all tumors. COL11A1 was 
located within the malignant cells in all biopsies. FN1 was also found in malignant PDAC 
cells and in immune cells in DLBCL. CTSB was located in macrophages in TNBC and 
PDAC, and tumor cells in DLBCL.  
 
Data resource 
All data in this paper are provided in a mine-able web-based resource 
http://www.canbuild.org.uk currently under construction. Users are able to download, 
visualize, analyse and integrate across datasets.  
 
Discussion 
In this paper we have profiled, for the first time, an evolving human metastatic 
microenvironment, using analysis that includes gene expression, matrix proteomics, 
  16 
cytokine/chemokine expression, ECM organization and biomechanical properties, all 
performed on the same sample. This gives a unique and informative snapshot of the evolving 
metastatic state of one type of ovarian cancer. Integration of the most significant features of 
this microenvironment may have identified a matrix response that is conserved in other 
cancers of epithelial or mesenchymal origins.  
Our study has also shown that conducting multi-level analysis with data integration on well-
characterized cancer biopsies with a range of disease involvement, and multiple analyses per 
sample, can identify important features representative of the evolving TME. This approach is 
complementary to ‘omic’ molecular cancer datasets that have larger numbers of samples. The 
data presented here provide a unique resource regarding molecular, cellular, and mechanical 
regulation in the tumor microenvironment and a template for bioengineers who are building 
complex tumor microenvironment models. 
Molecular genetics has revealed great intra- and inter-tumor heterogeneity. It is now accepted 
that malignant cell clones undergo Darwinian evolution, resulting in a high level of molecular 
heterogeneity. In contrast, this study shows that the interactions between malignant cells and 
the host to remodel the tissue matrix may be more consistent. It is already known that high 
lymphocyte density is a common indicator of good prognosis at different stages of disease in 
many malignancies including HGSOC (14). We suggest that another common feature of 
TMEs may be patterns of matrisome genes and proteins and that these also have prognostic 
significance.  
The up-regulated genes that were most significantly related to disease score in our analysis, 
COL11A1, COMP, VCAN, FN1, COL1A1 and CTSB have all been associated with cancer 
progression, poor prognosis and malignant cell invasion in ovarian and/or other cancers (42-
49). For example, fibronectin promotes ovarian cancer invasion and metastasis through an 
α5β1-integrin/c-Met/FAK/Src-dependent signaling pathway (44) and COL11A1 and VCAN 
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feature in a 10-gene poor prognostic signature of collagen-remodeling genes regulated by 
TGF-β signaling in ovarian cancer (45). More recently gene expression of COL11A1 showed 
a positive association with poor prognosis in several epithelial cancers (49). Importantly, the 
matrix index appears to correlate with certain immune cell signatures that are also known to 
influence prognosis. For example, the matrix index does not positively correlate with CD8 
molecular signatures, which are associated with good prognosis in HGSOC, but significantly 
correlates with Treg and Th2 signatures.  
We have not focused on proteases in this study. However, in our samples, normal tissue ECM 
stained highly positive and evenly for COL1A1, but COL1A1 staining in diseased sections, 
whilst still strong, appeared more uneven. In particular there was reduced staining around 
malignant cell areas. This may be due to expression of proteases such as MMP13, which 
degrade collagen structures (50), that we identified in our PLS analysis. Other matrix 
remodeling proteases that we identified such as MMP7, MMP11, CTSB, and ST14 are also 
able to degrade collagens, albeit to a lesser extent, but may also be capable of degrading 
matrix proteoglycans and glycoproteins (51,52). In addition to protease activity, the apparent 
reduction in COL1A1 by mass ratio (Figure 3A) was in part due to the relative increase in 
matrisome complexity in diseased tissues. Also, we used a modified matrisome analysis 
method which increased our protein detection coverage, at the cost of underestimating the 
absolute amount of large fibrous core matrisome proteins such as COL1A1. 
As we have shown, there was a core group of matrisome molecules that best predicted tissue 
modulus. This appears to be through an expansion of matrisome glycoproteins and 
proteoglycans (Figure 3A) and a reorganization of fibrillar collagens (Figure 3G). The 
expansion of the glycoprotein and proteoglycan compartment increases the potential for post-
translational modification within the extracellular space which could significantly alter the 
mechanical properties of the tissue, particularly through glycosylation and cross-linking (53). 
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For example, glycosaminoglycans on proteoglycans contribute to hydration, which 
contributes to tissue stiffness (54). Additionally, specific ECM cross-linking molecules, 
including the pro-lysyl hydroxylases which cross-link matrix proteins through collagen-like 
peptides, were associated with increasing disease in our samples (55). Molecules like 
COL11A1 and COMP are normally only present in stiffer tissues such as cartilage and bone, 
while VCAN plays a role in the morphogenesis of these stiffer tissues. In addition, collagens 
11 and 6 play roles in collagen fibril organization and matrix integrity.  
Tumor mechanics have a profound effect on fibroblasts and cancer cells and can promote 
tumor progression and metastasis (56). Stiffening of ECM creates a feed-forward self-
reinforcing loop that contributes to the activation state of the fibroblast (57). Elevated 
mechano-signalling in PDAC cells as a result of elevated tissue stiffening, promotes tumor 
progression and aggression (8). In breast tumors, the stiffest regions are located at the 
invasive margins and tumors harboring the stiffest regions are the most aggressive (58). 
There is a significant desmoplastic response in most solid tumors, but given that there is large 
intra- and inter-tumor heterogeneity it is important to understand why our index of matrisome 
gene expression defines patients with poor prognosis in multiple human cancers. The matrix 
index does not seem to be simply a measure of the amount of desmoplasia or stromal 
component that accompanies cancer growth. We believe that it is a measure of a type 
matrisome composition that is more able to promote tumor growth. We found a strong 
association between the density of -SMA and α-FAP positive cells, two markers commonly 
associated with activation of cancer associated fibroblasts, and disease score and there are 
several examples in the literature of poor prognostic fibroblast, desmoplastic, wound healing 
and stromal signatures in individual cancer types e.g. (39,59). As fibroblasts are the 
predominant matrix producing cells in many tissues this may, at least partially, explain the 
commonality of the matrix index in different cancers. It is also interesting that some of the 
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matrix index molecules we found to be down-regulated as disease increases (LAMB1, 
LAMC1, LAMA4, COL15A and HSPG2) are associated with the basement membrane which 
is vital for maintaining tissue homeostasis.  
Malignant cell response to tumor-associated fibrosis, and the stromal cell phenotypes that 
contribute to ECM deposition, can vary within and between major cancer types. This was 
shown in great detail recently in a study of experimental and human pancreatic cancers where 
a distinct malignant cell genotype modulated the fibrotic phenotype of the tissue and 
pathology (8). This does not argue against our finding because we have found the matrix 
index is variable between different cases of each cancer.  
As the predictive power of the matrix index was independent of age, stage and response to 
primary treatment, we suggest that the pattern of change in the matrisome may reflect 
increased propensity of the malignant cells to establish metastases. It is intriguing that five of 
the six up-regulated ECM genes in our matrix index (COMP, VCAN, FN1, COL1A1 and 
CTSB) are typical of pre-metastatic niches (60). Another explanation for the association with 
poor prognosis could be that this configuration of ECM molecules prevents infiltration or 
effector function of host anti-tumor immune cells. A stiffened matrix can compromise T-cell 
antigen presentation and proliferation as well as Th1-cell differentiation (61). In addition, the 
ECM acts as a reservoir for angiogenic factors and is important for migration of endothelial 
cells during neo-angiogenesis and vascular remodeling seen in cancer (62). 
Many of the matrix index molecules described above circulate systemically as fragments 
from protease remodeling, sometimes as neo-epitopes (63). Therefore, further investigation 
of the matrix index may have potential as a cancer diagnostic/prognostic blood test. 
If we have identified a common and especially detrimental signature of the tumor-associated 
matrisome, then agents that could target or reconfigure the cancer matrisome could have wide 
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applicability in solid cancers and may enhance the action of immunotherapies, especially 
given the association of high matrix index with immunosuppressive T cell signatures.  
Some molecules of the matrix index may also prove good targets for drug delivery to the 
tumor site. A recent study demonstrated collagen 1 targeting of an anti-EGFR mAb showed 
increase therapeutic efficacy (64). Targeting matrix index molecules which are not as 
ubiquitous as collagen 1 may provide a significant advancement to such strategies.  
 
 
Methods 
Ovarian cancer patient samples 
Patient samples were kindly donated by women with high-grade serous ovarian cancer 
(HGSOC) undergoing surgery at Barts Health NHS Trust between 2010 and 2014. Blood and 
tissue that was deemed by a pathologist to be surplus to diagnostic and therapeutic 
requirement were collected together with associated clinical data under the terms of the Barts 
Gynae Tissue Bank (HTA license number 12199. REC no: 10/H0304/14). Each patient gave 
written informed consent and the study was approved by a UK national review board. The 
studies were conducted in accordance with the Declaration of Helsinki and International 
Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS). 
 
RNA isolation and sequencing 
Total RNA was extracted from 10 x 50 μm cryosections from frozen tissue sections and 
placed directly into the RLT Plus buffer (Qiagen) and rigorously vortexed. Samples were 
then processed using Qiagen RNeasy Plus Micro kit according to manufacturer’s instructions. 
RNA quality was analyzed on agilent bioanalyzer 2100 using RNA PicoChips according to 
manufacturer’s instructions. RNA integrity numbers (RIN) were between 8.1 and 9.9. RNA-
Seq was performed by Oxford Gene Technology (Benbroke, UK) to ~42x mean depth on the 
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Illumina HiSeq2500 platform, strand-specific, generating 101bp paired-end reads, as 
previously described (65). The detailed methods regarding RNA sequencing and 
bioinformatic analysis are provided in the Supplementary Methods.  
 
Quantitative Proteomics 
The ECM component was enriched from frozen whole tissue sections (20 x 30 μm sections, 
approximately 40-50 mg of tissue) as previously described (17). The extracted proteins were 
reduced, alkylated and digested with trypsin. Peptides were separated by nanoflow ultra-high 
pressure liquid chromatography (UPLC, NanoAcquity, Waters) and analyzed by mass 
spectrometry using a LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific). The 
detailed methods of ECM component enrichment, peptide preparation, mass spectrometry 
and bioinformatics analysis are provided in the Supplementary Methods.  
 
Cytokine and chemokine analysis 
Cytokine and chemokines were assayed using Mesoscale Discovery Platform (MSD SI2400) 
according to manufacturer’s instructions. Cytokine panel 1(Human) K15050D, 
Proinflammatory panel 1(human) K0080087, and Chemokine panel 1(Human) K0080125 
were used. Samples used were lysates from the ECM-enrichment protocol (described above). 
The amount of total protein used from each sample was between 1 and 3 μg.  
 
Mechanical characterization 
Mechanical characterisation was performed on whole tissues using a flat-punch indentation 
methodology on an Instron ElectroPuls E1000 (Instron, UK) equipped with a 10 N load cell 
(resolution = 0.1 mN) in order to measure the modulus of the tissue samples(15)(Delaine-
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Smith et al., 2016). The detailed method of quantification is provided in the Supplementary 
Methods. 
 
Histochemical analysis 
Frozen tissues that were subsequently used for RNA, proteomics and cytokine analysis were 
cryosectioned to 8-10 µm slices. Sections were fixed in in 4 % paraformaldehyde (PFA) and 
stained with haematoxylin and eosin using standard methods. Tissues used in mechanical 
characterization were cut in half at the center of the tissue dye marked area and perpendicular 
to the direction of indentation while still frozen. Tissue was then fixed in 4 % PFA for 24 h 
and paraffin embedded and sectioned (8 µm) using standard procedures followed by H&E 
staining. All tissue sections were scanned using a 3DHISTECH Panoramic 250 digital slide 
scanner (3DHISTECH, Hungary) and the resulting scans were analysed using Definiens 
software (Definiens AG, Germany). Disease scores were determined firstly by manually 
defining regions of interest in the tissue that represented tumor, stroma, fat (adipocytes) or 
other (lymphatic structure) and then training the software to recognize these regions of 
interest. Disease score was expressed as a percentage of the whole tissue area that contained 
tumor and/or stroma (Figure 1B). Detailed methods of immunohistochemical analysis for 
quantification of immune cells, α-SMA and α-FAP positive cells, adipocyte diameters, ECM 
proteins and second-harmonic generation microscopy are provided in the Supplementary 
Methods. 
 
RNA in situ hybridization 
Chromogenic in situ hybridization for VCAN (Probe-Hs-VCAN, Cat No. 430071, Advanced 
Cell Diagnostics Inc. USA) was performed using the RNAscope 2.5 HD Detection Reagent 
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kit (Advanced Cell Diagnostics Inc.) according to the manufacturer’s instructions (see 
Supplementary Methods). 
 
Statistical and bioinformatics analysis 
All statistical analyses and graphics were performed in the statistical programming language 
R (version 3.1.3). Detailed methodology for PLS regression models, Matrix index and its 
clinical association across cancer types is provided in the Supplementary Methods. 
 
Accession Numbers 
RNA-Seq data have been deposited in Gene Expression Omnibus (GEO) under the accession 
number GSE71340. Proteomic data are available via the PRIDE database accession number 
PXD004060. 
 
Data availability 
All of the primary data are deposited at http://www.canbuild.org.uk. 
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Figure 1. Study design and sample description  
a) Overview of the samples and the analyses conducted on the same tissue specimen. b) Bar 
plot shows results from digital analysis of architecture of haematoxylin and eosin (H&E)-
stained samples based on percentage of malignant cell area (tumor), stroma, and adipocyte 
area, coloured blue, green and red respectively. The combined percentage area occupied by 
tumor and stroma was used to determine the ‘disease score’ of each sample. Each G number 
represents one sample. Upper microscope images show H&E staining of a biopsy and the 
same biopsy pseudo-coloured as malignant cell area (tumor) blue, stroma green and 
adipocyte area, red. Bottom images show four different H&E-stained samples representative 
of sample range with increasing disease score. c) Schematic of the PLS regression method 
used to define higher-order features of the tumor microenvironment from molecular 
components. 
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Figure 2. The cells of the TME change with disease score  
a) Adipocyte diameter negatively correlated with increasing disease score. Top panel, 
microscope images representative of low (left) and high (right) disease score tissue sections 
(stained for α-SMA by IHC) showing adipocytes. Scale-bar corresponds to 100µm. Bottom 
left panel, scatter plot illustrating mean ± sd of digitally quantified adipocyte diameter (linear 
regression, N = 16, R
2
 = 0.66, p = 0.0001). b) Correlation of -SMA positive cells against 
disease score. Top panel, representative low (left) and high (right) disease score tissue 
sections stained for -SMA by IHC. Scale-bar corresponds to 100µm. Bottom panel, 
quantification of -SMA+ area % against disease score (linear regression, N = 30, R2 = 0.83, 
p < 0.0001). c) Correlation of -FAP positive cells against disease score. Top panel, 
representative low (left) and high (right) disease score tissue sections stained for -FAP by 
IHC. Scale-bar corresponds to 100µm. Bottom panel, quantification of -FAP+ area % 
against disease score (power regression, N = 32, R
2
 = 0.77, p < 0.0001). d) Cleveland plots of 
immune cell counts against disease score (Spearman’s correlation, N = 34). e-f) Heatmap of 
pairwise Pearson’s correlation coefficients of e) immune cell counts (N = 34), f) MSD-
quantified cytokine/chemokine correlations against immune cell counts (N = 32).  h) IHC of 
IL16 in HGSOC omental biopsies. Scale-bars correspond to 100µm. g) Heatmap of pairwise 
Pearson’s correlation coefficients of MSD-quantified cytokine/chemokine (N = 32).  
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Figure 3. Identification of matrisome proteins and genes that define tissue architecture  
a) Matrisome data displayed as relative mass ratios. Top panels show individual matrisome 
proteins identified in low and high disease score tissue; bottom panels show the relative 
proportions of each of the major classes of matrisome proteins in lowest (N = 6) versus 
highest disease score (N = 10). b) Line graphs illustrating normalized protein abundance and 
local polynomial regression fitted trend lines of proteins that either decrease (top panel), or 
increase (bottom panel) with disease score. c) PLS-identified matrisome proteins and d) 
matrisome genes that define disease score. e) Scatter plot of gene and protein correlation with 
disease score, highlighted molecules denote significant correlations (Pearson’s correlation, N 
= 33, p < 0.05). f) IHC staining for four matrisome proteins, FN1, COMP, CTSB, COL11A1 
identified from PLS analysis as highly significantly related to disease score. Scale-bars 
correspond to 200µm. g) Collagen fiber alignment; top panel shows representative images of 
high and low disease score tissue sections visualised using second harmonic generation, and 
bottom panel, semi-quantification of fiber alignment from images plotted as number of fiber 
occurrences per angle bin (predominant fibre direction normalized to 0 degrees) with local 
polynomial regression fitted lines and disease color-coding.  
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Figure 4. Identification of molecular components that define tissue modulus  
a) Orientation of flat-punch indentation showing representative low and high disease score 
samples stained with H&E, dashed line indicates tissue area analysed for determining disease 
score. b) Representative load-displacement curve from loading phase obtained from high and 
low disease score samples. c) Optimal tissue modulus correlated against combined % tumor 
plus stroma (disease score) (N = 32, p < 0.05). d-f) Cross-validation plot of measured versus 
predicted tissue modulus values (diagonal line represents measured = predicted) and heatmap 
of PLS-identified d) matrisome proteins, e) matrisome genes, and f) all coding gene 
components that describe tissue modulus. Heatmap columns correspond to individual 
samples ordered by increasing tissue modulus.  (N = 29, 30 and 30, respectively). Rows 
ordered by decreasing model weight values.  
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Figure 5. A matrix signature that predicts survival in ovarian cancer 
a) Venn diagram showing the overlap of PLS-identified molecules associated to tissue 
modulus and disease score (DS) at both gene and protein level. A total of 22 ECM-associated 
molecules overlapped across all analyses, red colour denotes positive association and blue 
colour negative association of each molecule at gene (G) and protein (P) level with disease 
score and tissue modulus. b) Network of known protein:protein interactions from IntAct and 
BioGRID within the 22 ECM-associated. Visualisation was carried out using Cytoscape 
v.3.3.0. c) Based on gene expression levels of these molecules we calculated a matrix index 
as the ratio of average level of expression of genes positively associated to those negatively 
associated with disease score and tissue modulus. Scatter plots show the correlation of matrix 
index with tissue modulus (linear regression, N = 30, R
2
 = 0.74, p < 0.0001) and disease 
score (linear regression, N = 35, R
2
 = 0.76, p < 0.0001). d) Association of matrix index with 
immune gene signature expression. Barplot illustrates Spearman p-values, FDR corrected 
using the Benjamini & Hochberg method. Red denotes positive correlations, blue denotes 
negative and gray denotes insignificant associations. The dotted line specifies the significance 
cutoff p = 0.05. e) Kaplan-Meier survival curves with overall survival of TCGA and ICGC 
dataset for HGSOC divided by high or low matrix index. The x-axis is in the unit of years. f) 
Comparison of hazard ratio scores (HR, with 95% CI) derived from Cox proportional hazards 
model for matrix index and the indicated gene expression signatures extracted from literature 
on the ovarian TCGA dataset. Left panel corresponds to univariate analysis, right panel 
corresponds to multivariate analysis taking into account age, tumor stage, grade and treatment 
(i.e., primary therapy outcome success). The asterisks represent the significance in the KM 
analysis between the high- and low-index groups (***p < 0.001, **p < 0.01, *p < 0.05 
and0.05 < p < 0.1). 
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Figure 6. Matrix index reveals a common stromal reaction across cancers  
a) Kaplan-Meier survival curves with overall survival from the indicated datasets divided by 
high or low matrix index. The x-axis is in the unit of years. b) Multivariate hazard ratio (HR, 
with 95% CI) derived from a Cox proportional hazards regression model across cancer types / 
datasets using the matrix index. In each cancer, patients were split into high and low index 
groups, and their association with the overall survival (OS) was tested taking into account 
age, stage, grade (T-factor), and treatment factors. Asterisks represent the significance in the 
KM analysis between the high- and low-index groups (***p < 0.001, **p < 0.01, *p < 0.05 
and0.05 < p < 0.1). HR > 1 means that high index is inversely correlated with OS, while 
HR < 1 means high index positively correlated OS. c) Example IHC images from TNBC, 
PDAC and DLBCL biopsies digitally quantified using Definiens
TM
 software on cancer tissue 
array cores for matrix index proteins FN1, COL11A1, CTSB, and COMP. High intensity 
staining = red, medium = orange, low = yellow. d) Quantification of IHC staining on tissue 
arrays from TNBC, PDAC and DLBCL biopsies using Definiens
TM
 software. Box plots 
illustrate the percentage area of high intensity staining for each marker. Scale bar = 500µm. 
COL11A1 and FN1, N = 30, 36, 54; CTSB, N = 28, 35, 52; COMP, N = 29, 35, 54; for 
TNBC, PDAC and DLBCL respectively. 
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